Bipolar Disorder Market
Bipolar Disorder Market Size, Share & Trends Analysis Report by Drug Class (Mood Stabilizers, Antipsychotics, Antidepressants, Combination Therapies), By Disorder Type (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Episode (Manic Episodes, Depressive Episodes, Mixed Episodes), By Therapy (Pharmacotherapy, Psychotherapy, and Electroconvulsive Therapy (ECT)) and Forecast Period (2026–2035)
Industry Overview
Bipolar disorder market was valued at $9.7 billion in 2025 and is projected to reach $15.5 billion by 2035, growing at a CAGR of 4.8% from 2026 to 2035. Market growth is driven by increasing mental health awareness, rising diagnosis rates, and the expansion of pharmacological treatments, particularly atypical antipsychotics and long-acting injectables (LAIs). These therapies are gaining traction due to improved patient adherence and reduced relapse rates. Additionally, the shift toward precision psychiatry and the development of novel mechanisms such as glutamate modulators, are reshaping treatment paradigms. Pharmaceutical companies are increasingly focusing on targeted therapies that address both manic and depressive episodes, further strengthening the market outlook.
Recent developments highlight growing industry efforts to enhance both treatment innovation and patient support. In March 2025, H. Lundbeck A/S contributed nearly $300,000 through its U.S. Charitable Fund to the Depression and Bipolar Support Alliance (DBSA), aiming to expand peer support and mental health education programs. This initiative strengthens community-based care and improves access for individuals with mood disorders, indirectly supporting market growth. In December 2024, Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S announced Phase 3 clinical trial results of brexpiprazole in combination with sertraline for PTSD, showing significant improvement in symptoms compared to placebo. The study, published in JAMA Psychiatry, demonstrated strong efficacy and a favorable safety profile. This advancement highlights continued innovation in antipsychotic therapies, which also supports treatment development in bipolar disorder. Together, these innovations, along with ongoing patent expirations and rising generic penetration, are creating a balanced and competitive landscape between branded and generic drug manufacturers.
Market Dynamics
Antipsychotics Lead the Bipolar Disorder Treatment Landscape with Strong Clinical Efficacy
Antipsychotics continue to dominate the bipolar disorder market due to their strong clinical effectiveness, particularly in managing acute manic and mixed episodes. These drugs act on dopamine and serotonin pathways, helping stabilize mood and reduce symptom severity. Their effectiveness in manic and mixed episodes makes them a first-line treatment option in clinical practice. In February 2026, the U.S. FDA approved ) for treating bipolar I disorder and schizophrenia, further strengthening the role of next-generation antipsychotics in psychiatric care. This approval highlights ongoing innovation in pharmacotherapy and the development of safer, more effective treatment options. Additionally, the increasing adoption of atypical antipsychotics and long-acting injectables is improving patient adherence and long-term outcomes, reinforcing their leading position in the bipolar disorder market.
Bipolar I Disorder Dominates Market Demand Driven by Severe Clinical Burden
Bipolar I disorder accounts for the largest share of the bipolar disorder market due to its severe clinical manifestations and higher rates of hospitalization. The intensity of manic episodes and the need for continuous disease management significantly increase reliance on pharmacological treatments. These drives sustained demand for effective therapies targeting both acute and maintenance phases. In January 2025, Johnson & Johnson expanded its neuroscience portfolio through the acquisition of Intra-Cellular Therapies. This deal added CAPLYTA (lumateperone), an FDA-approved treatment for bipolar I and II depression. The drug’s flexibility as both monotherapy and adjunct therapy enhances treatment outcomes. Such strategic expansions highlight the growing focus on addressing the high unmet needs within the Bipolar I patient population.
Market Segmentation
- Based on drug class, the market is segmented into mood stabilizers, antipsychotics, antidepressants, and combination therapies.
- Based on disorder type, the market is segmented into bipolar I disorder, bipolar II disorder, and cyclothymic disorder.
- Based on episode, the market is segmented into manic episodes, depressive episodes, and mixed episodes.
- Based on therapy, the market is segmented into pharmacotherapy, psychotherapy, and electroconvulsive therapy (ECT).
Surging Demand for Bipolar Depression Therapies Accelerates Depressive Episode Segment Growth
Depressive episodes represent the fastest-growing segment in the bipolar disorder market due to high relapse rates and significant unmet treatment needs. The limited effectiveness of conventional antidepressants and frequent recurrence of symptoms are driving demand for more targeted therapies. In November 2025, Johnson & Johnson announced FDA approval of CAPLYTA (lumateperone) as an adjunctive treatment for major depressive disorder. Importantly, CAPLYTA is already approved for bipolar I and II depression, strengthening its relevance in managing depressive episodes. Clinical data demonstrated significant symptom improvement and potential remission benefits, addressing critical treatment gaps. This advancement highlights the increasing focus on innovative pharmacotherapy solutions, further accelerating growth in the depressive episodes segment.
Pharmacotherapy is the leading therapy in the market
Pharmacotherapy remains the cornerstone of treatment in the bipolar disorder market, encompassing medications such as mood stabilizers, antipsychotics, and antidepressants. It plays a vital role in controlling acute episodes and preventing long-term relapse. Ongoing advancements, including long-acting injectables and novel drug mechanisms, are improving treatment outcomes and patient adherence. As a result, pharmacotherapy continues to be the dominant and highest revenue-generating segment. In January 2026, clinical research published on PubMed Central reaffirmed the central role of pharmacological treatments in bipolar disorder management. The study highlighted that both acute and maintenance phases rely heavily on medication-based interventions. These findings further reinforce the importance of pharmacotherapy in ensuring effective symptom control and long-term disease management.
Regional Outlook
The global bipolar disorder market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America is the leading region in the market
North America dominates the bipolar disorder market due to strong healthcare infrastructure, high treatment adoption, and the presence of leading pharmaceutical companies. The region benefits from continuous innovation supported by regulatory agencies such as the U.S. FDA, which approved 46 novel drugs in 2025, reflecting sustained advancement in pharmaceutical R&D. This high level of drug approvals accelerates the availability of new CNS therapies, including treatments relevant to bipolar disorder. Additionally, favorable reimbursement policies and increasing mental health awareness contribute to higher diagnosis and treatment rates. The region also leads in clinical trials and adoption of advanced therapies such as long-acting injectables. Collectively, these factors reinforce North America’s leadership in the bipolar disorder treatment market.
Market Players Outlook
The major companies operating in the global Antibiotics market include Johnson & Johnson, AbbVie Inc., Bristol Myers Squibb, AstraZeneca plc, and Eli Lilly and Company, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative Protection development to maintain their market positioning.
Recent Development
- In February 2026, the Bristol Myers Squibb Foundation launched a national program to bolster mental health diversion initiatives for individuals with serious mental illnesses, including bipolar disorder. The program aims to improve access to care, reduce hospitalization rates, and support community-based mental health interventions.
- In September 2025, Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S received a Complete Response Letter from the U.S. FDA for their sNDA of REXULTI in combination therapy for PTSD. The FDA stated that the application did not provide sufficient evidence of effectiveness for approval. This development highlights regulatory challenges in CNS drug approvals, which also impact innovation and expansion in bipolar disorder therapies.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global bipolar disorder Market
- Based on the availability of data, information related to new Protections and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Bipolar Disorder Market Sales Analysis – Drug Class | Disorder Type| Episodes | Therapy ($ Million)
- Bipolar Disorder Market Sales Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Bipolar Disorder Market Trends
- Market Recommendations
- Market Determinants
- Market Drivers
- Drivers For Bipolar Disorder Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Bipolar Disorder Market: Impact Analysis
- Market Opportunities
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Bipolar Disorder Market Revenue and Share by Manufacturers
- Bipolar Disorder Type Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- Johnson & Johnson
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Bristol Myers Squibb
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- AstraZeneca plc
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Eli Lilly and Company
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Johnson & Johnson
- Key Company Analysis
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- Bipolar Disorder Market Sales Analysis By Drug Class ($ Million)
- Mood Stabilizers
- Antipsychotics
- Antidepressants
- Combination Therapies
- Bipolar Disorder Market Sales Analysis By Disorder Type ($ Million)
- Bipolar I Disorder
- Bipolar II Disorder
- Cyclothymic Disorder
- Bipolar Disorder Market Sales Analysis By Episode ($ Million)
- Manic Episodes
- Depressive Episodes
- Mixed Episodes
- Bipolar Disorder Market Sales Analysis By Therapy ($ Million)
- Pharmacotherapy
- Psychotherapy
- Electroconvulsive Therapy (ECT)
- Regional Analysis
- North American Bipolar Disorder Market Sales Analysis – Drug Class | Disorder Type| Episodes | Therapy | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Bipolar Disorder Market Sales Analysis – Drug Class | Disorder Type| Episodes | Therapy | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Bipolar Disorder Market Sales Analysis – Drug Class | Disorder Type| Episodes | Therapy | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Bipolar Disorder Market Sales Analysis – Drug Class | Disorder Type| Episodes | Therapy| Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Alkermes plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Apotex Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aurobindo Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bristol-Myers Squibb
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eli Lilly and Compan
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lundbeck A/S
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Intas Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lundbeck A/S
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lupin Limited
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sumitomo Pharma Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Torrent Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Viatris Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
1. Global Bipolar Disorder Market Research and Analysis Drug Class, 2025-2035 ($ Million)
2. Global Mood Stabilizers Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
3. Global Antipsychotics Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
4. Global Antidepressants Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
5. Global Combination Therapies Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
6. Global Bipolar Disorder Market Research and Analysis Disorder Type, 2025-2035 ($ Million)
7. Global Bipolar I Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
8. Global Bipolar II Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
9. Global Cyclothymic Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
10. Global Bipolar Disorder Market Research and Analysis Episode, 2025-2035 ($ Million)
11. Global Manic Episodes Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
12. Global Depressive Episodes Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
13. Global Mixed Episodes Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
14. Global Bipolar Disorder Market Research and Analysis By Therapy, 2025-2035 ($ Million)
15. Global Bipolar Disorder For Pharmacotherapy Market Research and Analysis By Region, 2025-2035 ($ Million)
16. Global Bipolar Disorder For Psychotherapy Market Research and Analysis By Region, 2025-2035 ($ Million)
17. Global Bipolar Disorder For Electroconvulsive Therapy (ECT) Market Research and Analysis By Region, 2025-2035 ($ Million)
18. Global Bipolar Disorder Market Research and Analysis By Region, 2025-2035 ($ Million)
19. North American Bipolar Disorder Market Research and Analysis By Country, 2025-2035 ($ Million)
20. North American Bipolar Disorder Market Research and Analysis By Drug Class, 2025-2035 ($ Million)
21. North American Bipolar Disorder Market Research and Analysis By Disorder Type, 2025-2035 ($ Million)
22. North American Bipolar Disorder Market Research and Analysis By Episode, 2025-2035 ($ Million)
23. North American Bipolar Disorder Market Research and Analysis By Therapy, 2025-2035 ($ Million)
24. European Bipolar Disorder Market Research and Analysis By Country, 2025-2035 ($ Million)
25. European Bipolar Disorder Market Research and Analysis By Drug Class, 2025-2035 ($ Million)
26. European Bipolar Disorder Market Research and Analysis By Disorder Type, 2025-2035 ($ Million)
27. European Bipolar Disorder Market Research and Analysis By Episode, 2025-2035 ($ Million)
28. European Bipolar Disorder Market Research and Analysis By Therapy, 2025-2035 ($ Million)
29. Asia-Pacific Bipolar Disorder Market Research and Analysis By Country, 2025-2035 ($ Million)
30. Asia-Pacific Bipolar Disorder Market Research and Analysis By Drug Class, 2025-2035 ($ Million)
31. Asia-Pacific Bipolar Disorder Market Research and Analysis By Disorder Type, 2025-2035 ($ Million)
32. Asia-Pacific Bipolar Disorder Market Research and Analysis By Episode, 2025-2035 ($ Million)
33. Asia-Pacific Bipolar Disorder Market Research and Analysis By Therapy, 2025-2035 ($ Million)
34. Rest of the World Bipolar Disorder Market Research and Analysis By Country, 2025-2035 ($ Million)
35. Rest of the World Bipolar Disorder Market Research and Analysis By Drug Class, 2025-2035 ($ Million)
36. Rest of the World Bipolar Disorder Market Research and Analysis By Disorder Type, 2025-2035 ($ Million)
37. Rest of the World Bipolar Disorder Market Research and Analysis By Episode, 2025-2035 ($ Million)
38. Rest of the World Bipolar Disorder Market Research and Analysis By Therapy, 2025-2035 ($ Million)
1. Global Bipolar Disorder Market Research and Analysis Drug Class, 2025 Vs 2035 ($ Million)
2. Global Mood Stabilizers Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
3. Global Antipsychotics Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
4. Global Antidepressants Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
5. Global Combination Therapies Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
6. Global Bipolar Disorder Market Research and Analysis Disorder Type, 2025 Vs 2035 ($ Million)
7. Global Bipolar I Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
8. Global Bipolar II Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
9. Global Cyclothymic Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
10. Global Bipolar Disorder Market Research and Analysis Episode, 2025 Vs 2035 ($ Million)
11. Global Manic Episodes Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
12. Global Depressive Episodes Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
13. Global Mixed Episodes Bipolar Disorder Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
14. Global Bipolar Disorder Market Research and Analysis By Therapy, 2025 Vs 2035 ($ Million)
15. Global Bipolar Disorder For Pharmacotherapy Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
16. Global Bipolar Disorder For Psychotherapy Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
17. Global Bipolar Disorder For Electroconvulsive Therapy (ECT) Market Research and Analysis By Region, 2025 Vs 2035 ($ Million)
18. US Bipolar Disorder Market Size, 2025-2035 ($ Million)
19. Canada Bipolar Disorder Market Size, 2025-2035 ($ Million)
20. UK Bipolar Disorder Market Size, 2025-2035 ($ Million)
21. France Bipolar Disorder Market Size, 2025-2035 ($ Million)
22. Germany Bipolar Disorder Market Size, 2025-2035 ($ Million)
23. Italy Bipolar Disorder Market Size, 2025-2035 ($ Million)
24. Spain Bipolar Disorder Market Size, 2025-2035 ($ Million)
25. Russia Bipolar Disorder Market Size, 2025-2035 ($ Million)
26. Rest of Europe Bipolar Disorder Market Size, 2025-2035 ($ Million)
27. India Bipolar Disorder Market Size, 2025-2035 ($ Million)
28. China Bipolar Disorder Market Size, 2025-2035 ($ Million)
29. Japan Bipolar Disorder Market Size, 2025-2035 ($ Million)
30. South Korea Bipolar Disorder Market Size, 2025-2035 ($ Million)
31. Australia and New Zealand Bipolar Disorder Market Size, 2025-2035 ($ Million)
32. ASEAN Economies Bipolar Disorder Market Size, 2025-2035 ($ Million)
33. Rest of Asia-Pacific Bipolar Disorder Market Size, 2025-2035 ($ Million)
34. Latin America Bipolar Disorder Market Size, 2025-2035 ($ Million)
35. Middle East and Africa Bipolar Disorder Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
